Abstract
A 33-year-old woman developed progressive ovarian cancer resistant to classical chemotherapy agents. We performed a bone marrow allograft after a myeloablative regimen. During hematological recovery, she developed acute graft-versus-host disease (GVHD). From this time her tumor diminished progressively. One year post transplant she has limited chronic liver GVHD and is still free of disease. The complete remission of advanced ovarian cancer was probably related to the GVHD which might therefore provide a new treatment option for this disease. Bone Marrow Transplantation (2000) 25, 681–682.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$259.00 per year
only $21.58 per issue
Buy this article
- Purchase on SpringerLink
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Ben-Yosef R, Nagler A, Slavin S . Graft-versus-tumor and graft-versus-leukaemia effect in patient with concurrent breast cancer and acute myelocytic leukaemia Lancet 1996 348: 1242–1243
Ueno NT, Rondon G, Mirza NQ et al. Allogeneic peripheral-blood progenitor-cell transplantation for poor-risk patients with metastatic breast cancer J Clin Oncol 1998 16: 986–993
Childs RW, Clave E, Tisdale J et al. Successful treatment of metastatic renal cell carcinoma with a nonmyeloablative allogeneic peripheral-blood progenitor-cell transplant: evidence for a graft-versus-tumor effect J Clin Oncol 1999 17: 2044–2049
Kaye SB, Eisenhauer EA, Hamilton TC . New non-cytotoxic approaches to ovarian cancer Ann Oncol 1999 10: 65–68
Legros M, Dauplat J, Fleury J et al. High-dose chemotherapy with hematopoietic rescue in patients with stage III to IV ovarian cancer: long-term results J Clin Oncol 1997 15: 1302–1308
Slavin S, Nagler A, Naparstek E et al. Nonmyeloablative stem cell transplantation and cell therapy as an alternative to conventional bone marrow transplantation with lethal cytoreduction for the treatment of malignant and nonmalignant hematologic diseases Blood 1998 3: 756–763
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Bay, J., Choufi, B., Pomel, C. et al. Potential allogeneic graft-versus-tumor effect in a patient with ovarian cancer. Bone Marrow Transplant 25, 681–682 (2000). https://doi.org/10.1038/sj.bmt.1702206
Received:
Accepted:
Published:
Issue date:
DOI: https://doi.org/10.1038/sj.bmt.1702206
Keywords
This article is cited by
-
Generation of tumour-specific cytotoxic T-cell clones from histocompatibility leucocyte antigen-identical siblings of patients with melanoma
British Journal of Cancer (2006)
-
Allogeneic stem cell transplantation for the treatment of advanced solid tumors
Springer Seminars in Immunopathology (2004)
-
Allogeneic hematopoietic stem cell transplantation in ovarian carcinoma: results of five patients
Bone Marrow Transplantation (2002)
-
Administration of low-dose interleukin-2 plus G-CSF/EPO early after autologous PBSC transplantation: effects on immune recovery and NK activity in a prospective study in women with breast and ovarian cancer
Bone Marrow Transplantation (2002)
